Explore AstraZeneca's strategic collaboration with CSPC Pharmaceuticals, focusing on AI-enabled drug discovery for chronic diseases, with potential milestones of over $5 billion.
Explore AstraZeneca PLC's June 2025 report detailing an insider transaction by CFO Aradhana Sarin, showcasing corporate governance through a charitable gift of shares.
AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.
Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.
Discover AstraZeneca's June 2025 Block Listing Interim Review, detailing securities management and share option plans. Key insights on compliance and financial performance.
AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.
AstraZeneca's Form 6-K reveals CEO Pascal Soriot's acquisition of 8,970 shares post-vesting. Key insights on performance, compliance, and tax obligations included.
AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.
AstraZeneca PLC completes the acquisition of EsoBiotec for up to $1 billion, enhancing its oncology portfolio with innovative cell therapies. Learn more about this transformative deal.
Discover key findings from AstraZeneca's 6-K filing on Imfinzi, highlighting significant advancements in treating high-risk non-muscle-invasive bladder cancer through the POTOMAC trial.
AstraZeneca's latest SEC Form 6-K reveals promising results from the DESTINY-Breast11 trial, highlighting Enhertu's potential to redefine treatment for high-risk HER2-positive breast cancer patients.
AstraZeneca's Calquence receives EU approval for untreated MCL, offering new hope with improved survival rates. This report details clinical trial results and market implications.